The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. population. The samples were stored after the researchers measured the T cell response.

Virus 52

Virus Immune Response Vaccine Research 52

The Pharma Data

SEPTEMBER 30, 2021

Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a replacement treatment that would keep metastatic cancers cornered from the lungs. It involves a bodily injection of a virus called the cowpea mosaic virus. 2021 Sep 14:e2101796. Adv Sci (Weinh).

Virus 52

Virus Engineering Treatment Research 52

The Pharma Data

JULY 29, 2021

econd Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury. Nasdaq: GILD) announced today its results of operations for the second quarter 2021. “We Second Quarter 2021 Financial Results. Total second quarter 2021 revenue of $6.2 As of June 30, 2021, Gilead had $7.4

Science 52

Science Production Treatment FDA 52

The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ – Laboratoire M2, Inc. Environmental Protection Agency (EPA) for use on hard non-porous surfaces against the SARS-CoV-2 virus that causes COVID-19. Environmental Protection Agency (EPA) for use on hard non-porous surfaces against the SARS-CoV-2 virus that causes COVID-19. ” continued Auray.

Virus 52

Virus Production International Marketing 52

The Pharma Data

AUGUST 3, 2021

The drug, which has undergone several clinical trials for human conditions but has not yet received approval to treat humans, inhibited the replication of SARS-CoV-2, the virus that causes COVID-19, in human cell cultures and in a mouse model, leading to much lower viral loads. 2021 Jul 20:eabg5827. A race to find COVID-19 treatments.

Virus 52

Virus Clinical Trials Drugs Laboratories 52

The Pharma Data

AUGUST 22, 2020

He said it was unlikely there would be a vaccine in 2020 but there was a “reasonable chance” of a working jab being ready for the following winter in 2021-22. But this rare interview reveals a lot more about his own views on how the virus is developing. Will children spread the virus to grandparents?

Virus 69

Virus Government Vaccine 69

The Pharma Data

JANUARY 11, 2021

It also has an HIV vaccine program, with separate phase 1 trials for two vaccines planned this year, and a program to develop a vaccine against the Nipah virus, which causes a range of illnesses, including fatal encephalitis. The company expects to supply 600 million to 1 billion doses of the vaccine in 2021 and 1.2 Source link.

Vaccine 52

Vaccine Clinical Trials Virus RNA 52

PLOS: DNA Science

JUNE 13, 2024

The virus SARS-CoV-2 emerged in Wuhan, home of a premiere research institute that focuses on viruses. An altered virus could have escaped. Evidence that the virus emerged, or escaped, from the wildlife trade is lacking. On April 15, 2021, I posted “ 3 Possible Origins of COVID: Lab Escapee, Evolution, or Mutator Genes?

Virus 52

Virus RNA DNA Science 52

Codon

AUGUST 26, 2024

When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use. These drugs would be ideal tools to bridge the wait for a vaccine against a quickly-spreading virus.

RNA 87

RNA Virus DNA Vaccine 87

Drug Discovery World

AUGUST 7, 2023

VDEC’s teams are already running Phase I clinical trials for a potential world-first vaccine against Crimean-Congo haemorrhagic fever, a virus that is spread by the bite of an infected tick and fatal in about 30% of cases.

Vaccine 130

Vaccine Virus Clinical Trials Disease 130

Chemical Biology and Drug Design

OCTOBER 10, 2023

Abstract Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a lethal disease that is prevalent worldwide. million people worldwide were living with HIV in 2021. Molecular insights of HIV Reverse transcriptase and it's inhibitors.

FDA Approval 100

FDA Approval Clinical Trials FDA Virus 100

The Pharma Data

AUGUST 15, 2021

2021 Apr 8:2021.04.08.438884. Melody Swartz, Jeffrey Hubbell and colleagues had previously developed a vaccine delivery tool called polymersomes – self-assembling, spherical nanoparticles that can encapsulate antigens and adjuvants (helper molecules that boost the immune response) and then release them inside immune cells.

Vaccine 52

Vaccine Virus Immune Response Clinical Trials 52

Drug Discovery World

SEPTEMBER 17, 2024

I was part of the team responsible for the spin out of Poolbeg from hVIVO plc in 2021 and it has been a privilege to adopt the role of lead scientist on a number of our clinical and pre-clinical programmes. The highlight of my career has undoubtedly been taking on the role of Principal Scientist at Poolbeg Pharma.

Research 221

Research Clinical Trials Disease Trials 221

The Pharma Data

JANUARY 11, 2021

Pfizer and BioNTech reported that their COVID-19 vaccine appears to be effective against a key mutation in new variants of the SARS-CoV-2 virus that causes COVID-19. SARS-CoV-2, the virus that causes COVID-19, has mutated into several strains. A study published by the U.S. which was first observed in the U.K., and now 501.V2,

Vaccine 52

Vaccine Clinical Trials Immune Response Virus 52

The Pharma Data

AUGUST 13, 2020

Inactivated whole virus vaccines: 60 million doses Valneva. The government says if the Janssen and Novavax vaccine trials go well, the first deliveries could take place in mid-2021. mRNA vaccines: 30 million doses BioNTech/Pfizer. Protein adjuvant vaccines: 60 million doses GSK/Sanofi; 60 million doses Novavax.

Vaccine 52

Vaccine Virus Government Clinical Trials 52

The Pharma Data

SEPTEMBER 30, 2021

We anticipate to sharing developments from our leading vaccines pipeline which underscore our ongoing commitment to uncovering insights which will help prevent severe infectious diseases at every stage of life, especially in diseases with an unmet need like respiratory syncytial virus.”.

Vaccine 52

Vaccine Research Virus Hospitals 52

The Pharma Data

NOVEMBER 27, 2020

UK firm develops solution for identifying whether patients are actually infectious from a virus or not. Iceni Diagnostics has revealed it is developing a new technology that can disclose if patients are actually infectious with a live virus or not. Read on to for the full insight.

Virus 52

Virus Vaccine International Immune Response 52

The Pharma Data

JANUARY 6, 2021

7, 2021 /PRNewswire/ — OyaGen, Inc. A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ ’ (2021) Viruses 13:52 [link]. ROCHESTER, N.Y. , Bennett et al., About OYA1. OYA1 (a.k.a.

Virus 40

Virus Clinical Trials Government Laboratories 40

The Pharma Data

JANUARY 21, 2021

21, 2021 — U.S. President Joe Biden has promised to re-energize the nation’s response to COVID-19, but one of his top pandemic advisors says that effort could be hamstrung by both the virus and the failings of the previous administration. © 2021 HealthDay. Posted: January 2021. THURSDAY, Jan. Source link.

Vaccine 52

Vaccine Virus RNA Research 52

Drug Discovery World

JULY 14, 2022

The same formulation of tecovirimat was approved by the US Food and Drug Administration (FDA) in 2018 and by Health Canada in late 2021 under the brand name TPOXX?for Tecovirimat works by interfering with the VP37 protein which is found on the surface of orthopoxviruses such as smallpox and monkeypox. for the treatment of smallpox.

Treatment 130

Treatment Pharmaceutical Companies Vaccine Virus 130

The Pharma Data

AUGUST 3, 2021

In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before. Our strong R&D pipeline has made further, decisive progress in the first half of 2021. In the first half of 2021, Boehringer Ingelheim generated strong net sales of around 2.3

Research 52

Research Clinical Trials Treatment Production 52

SCIENMAG: Medicine & Health

JULY 13, 2023

As a result of the COVID-19 pandemic, respiratory syncytial virus (RSV) surges in young children occurred outside the usual November to March season, when immune-based prophylactic is available to protect children at high risk for severe illness.

Hospitals 70

Hospitals Virus 70

The Pharma Data

JANUARY 15, 2021

16, 2021 /CNW/ – As the resurgence of COVID-19 activity continues in Canada , we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health , laboratory and healthcare capacity. OTTAWA, ON , Jan.

Virus 52

Virus Laboratories Hospitals Vaccine 52

The Pharma Data

DECEMBER 21, 2020

Kaiser Permanente has announced that it will extend its waiver for most member out-of-pocket costs for inpatient and outpatient services related to the treatment of COVID-19 through at least March 31, 2021 , or as long as the ongoing public health emergency lasts. OAKLAND, Calif. ,

Virus 52

Virus Clinical Research Regulations Treatment 52

Drug Discovery World

FEBRUARY 20, 2024

The contract was awarded by the Defense Threat Reduction Agency’s (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program, through the Medical Chemical, Biological, Radiological, and Nuclear (CBRN) Defense Consortium (MCDC) requirement 22-05, ‘Adjuvant Activity to Vaccines Prototype’.

Vaccine 130

Vaccine Immune Response Licensing Licensing 130

The Pharma Data

JANUARY 17, 2021

18, 2021 07:00 UTC. The Interim results are due to be announced 25 February 2021. BASINGSTOKE, England & MADISON, Wis.–( and £49.0m for the first half (six months to December 31, 2019: £36.6m).

Research Laboratories 52

Research Laboratories Regulations Production Laboratories 52

The Pharma Data

JANUARY 22, 2021

23, 2021 /CNW/ – As the resurgence of COVID-19 activity continues in Canada , we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health , laboratory and healthcare capacity. OTTAWA, ON , Jan.

Virus 40

Virus Vaccine Hospitals Laboratories 40

Drug Discovery World

JUNE 7, 2023

Under the leadership of CEO and Founder, Professor Helen McCarthy, pHion has made significant progress since invoX’s initial investment in June 2021, with advances made across all pre-clinical programs and the establishment of a laboratory in Belfast, Northern Ireland for the production of pHion’s mRNA vaccines.

Vaccine 130

Vaccine Testimonials Clinical Trials Laboratories 130

The Pharma Data

JANUARY 16, 2021

17, 2021 /CNW/ – As the resurgence of COVID-19 activity continues in Canada , we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians, public health , laboratory and healthcare capacity. OTTAWA, ON , Jan.

Hospitals 52

Hospitals Vaccine Laboratories Virus 52

The Pharma Data

JANUARY 26, 2021

Regeneron believes that the results could support emergency clearance of the treatment as a passive vaccine, which directly delivers antibodies into the body that combat the virus, compared to conventional vaccines that teach the immune system to make antibodies to the virus.

Vaccine 52

Vaccine Virus Research Laboratories FDA 52

Drug Target Review

JUNE 1, 2023

La Jolla Institute for Immunology (LJI), US, scientists demonstrated how antibodies obtained from a clinical study participant attach to the SARS-CoV-2 spike protein and neutralise the virus. The vaccine prompts the body to produce the spike protein, which allows the immune system to develop antibodies against the real virus.

Virus 97

Virus Vaccine Immune Response Research 97

Drug Discovery World

OCTOBER 31, 2022

The researchers suggest that non-pharmaceutical interventions, including masks, prophylactic antibody treatment, and anti-viral treatment after acquisition of the virus are important tools to consider for additional protection against severe Covid-19 in immunocompromised adults. . Lower protection despite boosters .

Vaccine 130

Vaccine Virus Hospitals Treatment 130

Drug Discovery World

APRIL 20, 2023

To date, it seems that the likely mechanism of post- Covid-19 cognitive impairment is neuroinflammation triggered by the peripheral / systemic inflammation caused by the virus. 2021, doi: 10.1038/ s41598-021-92045-x. 2021, doi: 10.1016/j.eclinm.2021.101019. S Bliddal et al., HE Davis et al., 2021.101019. M Taquet et al.,

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

Drugs.com

JULY 13, 2023

WEDNESDAY, July 12, 2023 -- New research shows that humans and deer passed the coronavirus back and forth in late 2021 and early 2022, raising concerns that this animal reservoir could become a source of new variants. Humans passed the virus to.

Virus 40

Virus Research 40

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. It has been well established that exposure to wild-type AAV results in priming of the immune system against the virus. Adeno-associated virus vector as a platform for gene therapy delivery.

Engineering 105

Engineering Virus Therapies Immune Response 105

The Pharma Data

DECEMBER 28, 2020

New York City issued a competitive request for proposal (RFP) for the 2021 school year, and we are excited to have been selected from the many labs who replied. We look forward to continuing to do our part to help keep schools safe through the remainder of the 2021 school year,” added Perthuis. TEMPLE CITY, Calif.,

Virus 52

Virus Hospitals Marketing International 52

The Pharma Data

JANUARY 15, 2021

15, 2021 — Immunity against the new coronavirus can last for at least five months in most people who have been infected, British researchers report. However, the researchers said that even if a previously infected person has immunity, they may still be able to carry the virus and infect others. © 2021 HealthDay.

Virus 52

Virus Vaccine Research 52